Bayer Capital Corporation B.V., founded in 2000 and based in the Netherlands, serves as a key component of Bayer AG's strategic financial operations. The company primarily focuses on providing financing solutions through capital markets, enabling innovative R&D and operational efficiencies within the Bayer Group.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| BAYNGR 1.50% 2026-06-26 EURBayer Capital Corporation B.V. | Netherlands | 2026-06-26 | 1.500 | 2.33 |
| BAYNGR 2.13% 2029-12-15 EURBayer Capital Corporation B.V. | Netherlands | 2029-12-15 | 2.125 | 3.06 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Bayer Capital Corporation B.V. has established a solid reputation in the bond market, first issuing corporate bonds in 2004 to enhance corporate liquidity. Notable issuances include a €500 million bond in 2019 aimed at refinancing existing debts, which achieved a favorable yield of 1.5%, well below industry averages. The company’s bonds are often characterized by their attractive interest rates and flexible maturity options, positioning them as an appealing choice for investors seeking stable returns. Recently, Bayer has reaffirmed its commitment to sustainable financing, aligning future bond issuances with environmental and social governance criteria to attract socially responsible investors.